CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Summary

Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland. Researchers believe a new drug called CUDC-907 may be able to help people with thyroid cancer that has spread or has gotten worse. Objective: To see if CUDC-907 will shrink tumors in people with advanced thyroid cancer. Eligibility: People at least 18 years old who have been diagnosed with locally advanced and metastatic thyroid cancer. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Electrocardiogram (ECG) heart test. Review of their symptoms and how they perform normal activities A scan will be performed. Some will have a computed tomographic scan (CT) that takes pictures of the body using a small amount of radiation. Some will have magnetic resonance imaging (MRI) that uses a magnetic field to take pictures. Bone scan (some participants) Fludeoxyglucose (FDG) positron emission tomography (PET) scan to produce a tumor image. A sample of their tumor from a previous surgery. They may have a biopsy of their tumor if a tumor sample is not available from a previous surgery. Participants will be given CUDC-907 in tablet form. They will take it by mouth once a day for 5 days, then take 2 days off, each week. While taking the study drug, participants will have study visits that repeat the screening tests. After they stop treatment, participants will have 3 follow-up visits over a year. They will repeat some tests. Then participants will be contacted by phone or e-mail every 6 months....

Timeline

Start

2016-12-22

Primary completion

2018-02-12

Completion

2018-02-12

Outcome

Outcome not reported

Stopped: “Study was closed because investigator left the National Institutes of Health.”

Publications

• Background Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998 Jun;22(6):569-74. doi: 10.1007/s002689900436.
• Background Nilubol N, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer. 2015 Apr 1;121(7):1017-24. doi: 10.1002/cncr.29123. Epub 2014 Nov 25.
• Background Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005 Apr 1;103(7):1330-5. doi: 10.1002/cncr.20936.

Drugs

Indications